Evidence map›Paper›PMID 37350332›Full record

ArticleACS applied materials & interfaces2023

β-Glucan-Mediated Oral Codelivery of 5FU and Bcl2 siRNA Attenuates Stomach Cancer.

Humayra Afrin, Stephanie Vargas Esquivel, Raj Kumar, Md Ikhtiar Zahid, Beu Oporeza, Md Fashiar Rahman, Thomas Boland, Md Nurunnabi

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied materials & interfaces, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Humayra AfrinEnvironmental Science & Engineering, University of Texas at El Paso, El Paso, Texas 79965, United States.ORCID 0000-0002-2720-1369
Stephanie Vargas EsquivelDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Texas at El Paso, El Paso, Texas 79902, United States.
Raj KumarDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Texas at El Paso, El Paso, Texas 79902, United States.
Md Ikhtiar ZahidEnvironmental Science & Engineering, University of Texas at El Paso, El Paso, Texas 79965, United States.
Beu OporezaBiomedical Engineering, College of Engineering, University of Texas at El Paso, El Paso, Texas 79965, United States.
Md Fashiar RahmanDepartment of Industrial, Manufacturing and Systems Engineering, University of Texas at El Paso, El Paso, Texas 79965, United States.
Thomas BolandBiomedical Engineering, College of Engineering, University of Texas at El Paso, El Paso, Texas 79965, United States.ORCID 0000-0003-2161-5699
Md NurunnabiEnvironmental Science & Engineering, University of Texas at El Paso, El Paso, Texas 79965, United States.ORCID 0000-0003-4457-3401
The University of Texas at El Paso · US

Funding

NIH HHS R03 OD032624
6 · The paper itself

Abstract

Based on cancer-related deaths, stomach cancer is ranked fifth, and first among Hispanics. Lack of technologies for early diagnosis and unavailability of target-specific therapeutics are largely the causes of the poor therapeutic outcomes from existing chemotherapeutics. Currently available therapeutic modalities are invasive and require systemic delivery, although the cancer is localized in the stomach at its early stage. Therefore, we hypothesize that an oral local delivery approach can extend the retention duration of the therapeutics modalities within the stomach and thereby enhance therapeutic efficacy. To accomplish this, we have developed a ß-glucan (BG)-based oral delivery vehicle that can adhere to the mucus lining of the stomach for an extended period while controlling the release of Bcl2 siRNA and 5-fluorouracil (5FU) payload for over 6 h. We found that Bcl2 siRNA selectively knocked down the Bcl2 gene in a C57BL/6 stomach cancer mouse model followed by upregulation of apoptosis and remission of cancer. BG was found to be very effective in maintaining the stability of siRNA for at least 6 h, when submerged in simulated gastric juice tested in vitro. To investigate the potential therapeutic effects in vivo, we used a stomach cancer mouse model, where C57BL/6 mice were treated with 5FU, BG/5FU, siRNA, BG/siRNA, and BG/5FU/siRNA. Higher inhibition of Bcl2 and therapeutic efficacy were observed in mice treated with BG/5FU/siRNA confirmed with Western blotting and a TUNEL assay. Significant reduction in the tumor region was observed with histology (H&E) and immunohistochemistry (Ki67, TUNEL, and Bcl2) analyses. Overall, the oral formulation shows improved efficacy with nonsignificant side effects compared to the conventional treatment tested in the gastric cancer mouse model.

Indexed as

beta-GlucansStomach NeoplasmsAnimalsFluorouracilMiceMice, Inbred C57BLRNA, Small Interferingbeta-GlucansFluorouracilRNA, Small Interferingoral biologicsoral local deliverystomach cancerstomach specific

Identifiers

PMID37350332
PMCPMC10787598
OpenAlexW4381715992

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.